The participation of the University of Pennsylvania in ECOG represents a combined group effort among many individuals aimed at improving the total care of cancer patients. The major activity of this group is directed towards innovative studies of new chemotherapeutic approaches alone, or in combination, and frequently with surgery or radiation therapy. The University of Pennsylvania Cancer Center provides the focal point for these activities at Penn. The University of Pennsylvania has established an outstanding ECOG membership record in terms of: senior administrative leadership positions throughout ECOG; major input into the disease-oriented and modality research strategies of the Group; increasing patient accrual (including a high percentage of multi-modality protocol entries); high quality scientific data; and an interdisciplinary team committed to cooperative group trials. Scientific input has been broad across all disciplines and involves chairmanship of major ECOG committees, group-wide ECOG protocols, as well as the development of pilot studies. During the projected grant period, it is expected that our scientific and administrative leadership will continue, and that our patient accrual will further increase. We continue to expand our disease-specific orientation beyond hematologic malignancies, breast and gastrointestinal cancer, into lung cancer and melanoma trials. We will explore innovative experimental approaches developed at the Cancer Center in the areas of antisense oligodeoxynucleotides, unique chemopreventative agents, bone marrow transplantation, and radiation chemotherapy interactions. We will further expand our multi-modality research, including the active participation of surgical oncologists, urologists, and gynecologic oncologists. Thus, ECOG serves as an effective partner with the University of Pennsylvania Cancer Center's intramural program of clinical research, patient care, and training future oncologists. The combined result of our ECOG and Cancer Center programs has been improved therapy for patients with malignant disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA015488-23
Application #
2086351
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1978-06-01
Project End
1999-04-30
Budget Start
1995-05-01
Budget End
1996-04-30
Support Year
23
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Lubner, Sam; Feng, Yang; Mulcahy, Mary et al. (2018) E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors. Oncologist 23:1006-e104
Stock, W; Diouf, B; Crews, K R et al. (2017) An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia. Clin Pharmacol Ther 101:391-395
Garg, Madhur K; Zhao, Fengmin; Sparano, Joseph A et al. (2017) Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). J Clin Oncol 35:718-726
Pine, Alexander B; Lee, Eun-Ju; Sekeres, Mikkael et al. (2017) Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States. Transfusion 57:289-295
Roberts, Kathryn G; Gu, Zhaohui; Payne-Turner, Debbie et al. (2017) High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. J Clin Oncol 35:394-401
Haas, Naomi B; Manola, Judith; Uzzo, Robert G et al. (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-16
Wilson, Melissa A; Zhao, Fengmin; Khare, Sanika et al. (2016) Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clin Cancer Res 22:374-82
Kumar, Anita J; Gimotty, Phyllis A; Gelfand, Joel M et al. (2016) Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII. Am J Hematol 91:1107-1112
Ganzel, Chezi; Manola, Judith; Douer, Dan et al. (2016) Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008. J Clin Oncol 34:3544-3553
Williams, Michael E; Hong, Fangxin; Gascoyne, Randy D et al. (2016) Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol 173:867-75

Showing the most recent 10 out of 120 publications